{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:15:28Z","timestamp":1784139328905,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_12023\/25"],"award-info":[{"award-number":["MC_UU_12023\/25"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ejca.2017.07.003","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T17:46:32Z","timestamp":1502214392000},"page":"88-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":135,"special_numbering":"C","title":["Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A\u00a0systematic review and meta-analysis"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-7457","authenticated-orcid":false,"given":"Larysa H.M.","family":"Rydzewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Burdett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thian","family":"Kheoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Miladinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa R.","family":"Spears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NamPhuong","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne F.","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2017.07.003_bib1","doi-asserted-by":"crossref","first-page":"R305","DOI":"10.1677\/ERC-10-0187","article-title":"An update on androgen deprivation therapy for prostate cancer","volume":"17","author":"Sharifi","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"5B","key":"10.1016\/j.ejca.2017.07.003_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0022-4731(85)80024-8","article-title":"Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival","volume":"23","author":"Labrie","year":"1985","journal-title":"J Steroid Biochem"},{"issue":"7","key":"10.1016\/j.ejca.2017.07.003_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-10-0567","article-title":"New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway","volume":"17","author":"Attard","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.ejca.2017.07.003_bib4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2017.07.003_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/iju.13091","article-title":"Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer","volume":"23","author":"Shiota","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.ejca.2017.07.003_bib6","article-title":"Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","author":"Gillessen","year":"2017","journal-title":"Eur Urol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2017.07.003_bib7","first-page":"P351","article-title":"Timely and reliable evaluation of the effects of interventions: a framework for adaptive meta-analysis (FAME)","volume":"18","author":"Tierney","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.ejca.2017.07.003_bib8","series-title":"Systematic review and meta-analysis of the effects of abiraterone for hormone-sensitive metastatic prostate cancer","author":"Rydzewska","year":"2017"},{"issue":"16","key":"10.1016\/j.ejca.2017.07.003_bib9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.003_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.07.003_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.07.003_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.07.003_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ejca.2017.07.003_bib14","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","article-title":"Chapter 9: analysing data and undertaking meta-analyses","author":"Deeks","year":"2011"},{"key":"10.1016\/j.ejca.2017.07.003_bib15","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2017.07.003_bib16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jclinepi.2010.11.016","article-title":"A critical review of methods for the assessment of patient-level interactions in individual patient data (IPD) meta-analysis of randomised trials, and guidance for practitioners","volume":"64","author":"Fisher","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2017.07.003_bib17","doi-asserted-by":"crossref","first-page":"j573","DOI":"10.1136\/bmj.j573","article-title":"Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?","volume":"356","author":"Fisher","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2017.07.003_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice \u2013 stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2017.07.003_bib19","article-title":"Randomised phase 3 trial of enzalutamide in first line androgen deprivation for metastatic prostate cancer: ENZAMET (ANZUP 1304)","volume":"25","author":"Davis","year":"2015","journal-title":"Ann Oncol"},{"issue":"Suppl. 6","key":"10.1016\/j.ejca.2017.07.003_bib20","article-title":"Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial","volume":"27","author":"Stenzl","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2017.07.003_bib21","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1016\/S1569-9056(17)30272-5","article-title":"A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS)","volume":"16","author":"Smith","year":"2017","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.ejca.2017.07.003_bib22","series-title":"Cochrane handbook for systematic reviews of interventions","first-page":"95","article-title":"Searching for studies","author":"Lefebvre","year":"2008"},{"issue":"1","key":"10.1016\/j.ejca.2017.07.003_bib23","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"J Med Libr Assoc"},{"key":"10.1016\/j.ejca.2017.07.003_bib24","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","author":"Wanling","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:21:26Z","timestamp":1760732486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917311103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":24,"alternative-id":["S0959804917311103"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A\u00a0systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}